Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade

Jain, Aditya; Zhang, Shijia; Shanley, Ryan; Fujioka, Naomi; Kratzke, Robert A.; Patel, Manish R.; Kulkarni, Amit

doi:10.1007/s00262-022-03320-3

Cited by 3 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some cancers, like non-small cell lung cancer (NSCLC) and melanoma, have been shown by multiple studies to promote the obesity paradox 16,17,21,82,84,[92][93][94][95] . Other cancers, such as renal cell carcinoma (RCC), have had several studies conducted indicating that obesity is not associated with improved survival, predictive of ICI response, or is even associated with poorer outcome 51,90,91 .…”

Section: The Obesity Paradox and Immune Checkpoint Inhibitors (Ici)mentioning

confidence: 99%

“…In some studies, a broad definition has been applied assessing both overweight and obese populations together, utilizing a BMI > 25, while other analyses have considered only those with BMI > 30 22,82 . Finally, BMI scores of even greater than 40 and up are being observed and this further complicates interpretation given that morbidly obese individuals also present with co-morbidities 21,92 .…”

Section: The Obesity Paradox and Immune Checkpoint Inhibitors (Ici)mentioning

confidence: 99%

“…Additional studies have identified nuance in the BMI obesity paradox, observing that the association of BMI and survival is not always linear. These studies identify that increasing BMI appears to be beneficial, until a threshold, in which increases in BMI are no longer associated with improved ICI response 21,92 . Interestingly, ICI dose has corelated with outcome, where high BMI was associated with improved overall survival, yet this was utilizing weight-based dosing administration, rather than a fixed regimen 22 .…”

Section: The Obesity Paradox and Immune Checkpoint Inhibitors (Ici)mentioning

confidence: 99%

See 2 more Smart Citations

Potential roles of sex-linked differences in obesity and cancer immunotherapy: revisiting the obesity paradox

Vick,

Rosario,

Riess

et al. 2024

npj Metab Health Dis

View full text Add to dashboard Cite

Obesity, a condition of excess adiposity usually defined by a BMI > 30, can have profound effects on both metabolism and immunity, connecting the condition with a broad range of diseases, including cancer and negative outcomes. Obesity and cancer have been associated with increased incidence, progression, and poorer outcomes of multiple cancer types in part due to the pro-inflammatory state that arises. Surprisingly, obesity has also recently been demonstrated in both preclinical models and clinical outcomes to be associated with improved response to immune checkpoint inhibition (ICI). These observations have laid the foundation for what has been termed the “obesity paradox”. The mechanisms underlying these augmented immunotherapy responses are still unclear given the pleiotropic effects obesity exerts on cells and tissues. Other important variables such as age and sex are being examined as further affecting the obesity effect. Sex-linked factors exert significant influences on obesity biology, metabolism as well as differential effects of different immune cell-types. Age can be another confounding factor contributing to the effects on both sex-linked changes, immune status, and obesity. This review aims to revisit the current body of literature describing the immune and metabolic changes mediated by obesity, the role of obesity on cancer immunotherapy, and to highlight questions on how sex-linked differences may influence obesity and immunotherapy outcome.

show abstract

Section: The Obesity Paradox and Immune Checkpoint Inhibitors (Ici)mentioning

confidence: 99%

Section: The Obesity Paradox and Immune Checkpoint Inhibitors (Ici)mentioning

confidence: 99%

Section: The Obesity Paradox and Immune Checkpoint Inhibitors (Ici)mentioning

confidence: 99%

See 1 more Smart Citation

Potential roles of sex-linked differences in obesity and cancer immunotherapy: revisiting the obesity paradox

Vick,

Rosario,

Riess

et al. 2024

npj Metab Health Dis

View full text Add to dashboard Cite

show abstract

Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle

Hes,

Jagoe

2023

BJC Rep

View full text Add to dashboard Cite

The gut microbiome is emerging as an important predictor of response to immune checkpoint inhibitor (ICI) therapy for patients with cancer. However, several nutrition-related patient characteristics, which are themselves associated with changes in gut microbiome, are also prognostic markers for ICI treatment response and survival. Thus, increased abundance of Akkermansia muciniphila, Phascolarctobacterium, Bifidobacterium and Rothia in stool are consistently associated with better response to ICI treatment. A. muciniphila is also more abundant in stool in patients with higher muscle mass, and muscle mass is a strong positive prognostic marker in cancer, including after ICI treatment. This review explores the complex inter-relations between the gut microbiome, diet and patient nutritional status and the correlations with response to ICI treatment. Different multivariate approaches, including archetypal analysis, are discussed to help identify the combinations of features which may select patients most likely to respond to ICI treatment.

show abstract

Body Composition and Clinical Outcomes in Esophageal Cancer Patients Treated with Immune Checkpoint Inhibitors

Kosumi,

Baba,

Hara

et al. 2024

Ann Surg Oncol

View full text Add to dashboard Cite

Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade

Cited by 3 publications

References 22 publications

Potential roles of sex-linked differences in obesity and cancer immunotherapy: revisiting the obesity paradox

Potential roles of sex-linked differences in obesity and cancer immunotherapy: revisiting the obesity paradox

Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle

Body Composition and Clinical Outcomes in Esophageal Cancer Patients Treated with Immune Checkpoint Inhibitors

Contact Info

Product

Resources

About